Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
470.00
-7.32 (-1.53%)
Feb 18, 2026, 11:38 AM EST - Market open
Vertex Pharmaceuticals Employees
Vertex Pharmaceuticals had 6,400 employees as of December 31, 2025. The number of employees increased by 300 or 4.92% compared to the previous year.
Employees
6,400
Change (1Y)
300
Growth (1Y)
4.92%
Revenue / Employee
$1,875,203
Profits / Employee
$617,688
Market Cap
119.40B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 6,400 | 300 | 4.92% |
| Dec 31, 2024 | 6,100 | 700 | 12.96% |
| Dec 31, 2023 | 5,400 | 600 | 12.50% |
| Dec 31, 2022 | 4,800 | 900 | 23.08% |
| Dec 31, 2021 | 3,900 | 500 | 14.71% |
| Dec 31, 2020 | 3,400 | 400 | 13.33% |
| Dec 31, 2019 | 3,000 | 500 | 20.00% |
| Dec 31, 2018 | 2,500 | 200 | 8.70% |
| Dec 31, 2017 | 2,300 | 150 | 6.98% |
| Dec 31, 2016 | 2,150 | 200 | 10.26% |
| Dec 31, 2015 | 1,950 | 120 | 6.56% |
| Dec 31, 2014 | 1,830 | 30 | 1.67% |
| Dec 31, 2013 | 1,800 | -400 | -18.18% |
| Dec 31, 2012 | 2,200 | 200 | 10.00% |
| Dec 31, 2011 | 2,000 | 309 | 18.27% |
| Dec 31, 2010 | 1,691 | 259 | 18.09% |
| Dec 31, 2009 | 1,432 | 99 | 7.43% |
| Dec 31, 2008 | 1,333 | 183 | 15.91% |
| Dec 31, 2007 | 1,150 | 188 | 19.54% |
| Dec 31, 2006 | 962 | 149 | 18.33% |
| Dec 31, 2005 | 813 | 77 | 10.46% |
| Dec 31, 2004 | 736 | 12 | 1.66% |
| Dec 31, 2003 | 724 | -256 | -26.12% |
| Dec 31, 2002 | 980 | -20 | -2.00% |
| Dec 31, 2001 | 1,000 | 545 | 119.78% |
| Dec 31, 2000 | 455 | 102 | 28.90% |
| Dec 31, 1999 | 353 | 13 | 3.82% |
| Dec 31, 1998 | 340 | 120 | 54.55% |
| Dec 31, 1997 | 220 | 42 | 23.60% |
| Dec 31, 1996 | 178 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Regeneron Pharmaceuticals | 15,410 |
| BeOne Medicines AG | 11,000 |
| BioNTech SE | 6,772 |
| Incyte | 2,844 |
| Genmab | 2,681 |
| Alnylam Pharmaceuticals | 2,500 |
| argenx SE | 1,599 |
| Insmed | 1,271 |
VRTX News
- 19 hours ago - Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3 - Business Wire
- 5 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments - Reuters
- 5 days ago - Vertex Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 9 days ago - Vertex Q4 Earnings Preview: What To Expect This Week - Seeking Alpha
- 15 days ago - WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager - PRNewsWire
- 22 days ago - GreensKeeper Value Fund Q4 2025 Portfolio Update: Long-Term Winners - Seeking Alpha
- 4 weeks ago - Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th - Business Wire